uniQure (QURE) Competitors $14.44 +0.13 (+0.91%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$14.54 +0.10 (+0.66%) As of 07/8/2025 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock QURE vs. PTGX, VKTX, MLTX, MTSR, MOR, KYMR, IMVT, CRNX, ALVO, and HCMShould you be buying uniQure stock or one of its competitors? The main competitors of uniQure include Protagonist Therapeutics (PTGX), Viking Therapeutics (VKTX), MoonLake Immunotherapeutics (MLTX), Metsera (MTSR), MorphoSys (MOR), Kymera Therapeutics (KYMR), Immunovant (IMVT), Crinetics Pharmaceuticals (CRNX), Alvotech (ALVO), and HUTCHMED (HCM). These companies are all part of the "pharmaceutical products" industry. uniQure vs. Its Competitors Protagonist Therapeutics Viking Therapeutics MoonLake Immunotherapeutics Metsera MorphoSys Kymera Therapeutics Immunovant Crinetics Pharmaceuticals Alvotech HUTCHMED Protagonist Therapeutics (NASDAQ:PTGX) and uniQure (NASDAQ:QURE) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations. Which has higher valuation and earnings, PTGX or QURE? Protagonist Therapeutics has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProtagonist Therapeutics$434.43M7.09$275.19M$0.7566.27uniQure$27.12M29.17-$239.56M-$4.39-3.29 Is PTGX or QURE more profitable? Protagonist Therapeutics has a net margin of 27.04% compared to uniQure's net margin of -1,077.05%. Protagonist Therapeutics' return on equity of 9.22% beat uniQure's return on equity.Company Net Margins Return on Equity Return on Assets Protagonist Therapeutics27.04% 9.22% 8.31% uniQure -1,077.05%-483.87%-34.28% Does the media refer more to PTGX or QURE? In the previous week, Protagonist Therapeutics had 1 more articles in the media than uniQure. MarketBeat recorded 3 mentions for Protagonist Therapeutics and 2 mentions for uniQure. Protagonist Therapeutics' average media sentiment score of 0.98 beat uniQure's score of -0.33 indicating that Protagonist Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive uniQure 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend PTGX or QURE? Protagonist Therapeutics currently has a consensus price target of $66.10, suggesting a potential upside of 33.00%. uniQure has a consensus price target of $37.82, suggesting a potential upside of 161.90%. Given uniQure's higher possible upside, analysts plainly believe uniQure is more favorable than Protagonist Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Protagonist Therapeutics 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00uniQure 0 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 2.91 Do insiders & institutionals hold more shares of PTGX or QURE? 98.6% of Protagonist Therapeutics shares are held by institutional investors. Comparatively, 78.8% of uniQure shares are held by institutional investors. 4.9% of Protagonist Therapeutics shares are held by company insiders. Comparatively, 4.8% of uniQure shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more volatility and risk, PTGX or QURE? Protagonist Therapeutics has a beta of 2.26, meaning that its share price is 126% more volatile than the S&P 500. Comparatively, uniQure has a beta of 0.08, meaning that its share price is 92% less volatile than the S&P 500. SummaryProtagonist Therapeutics beats uniQure on 14 of the 17 factors compared between the two stocks. Get uniQure News Delivered to You Automatically Sign up to receive the latest news and ratings for QURE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding QURE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QURE vs. The Competition Export to ExcelMetricuniQureMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$783.84M$2.88B$5.47B$8.95BDividend YieldN/A2.46%5.25%4.06%P/E Ratio-3.2920.8027.0020.10Price / Sales29.17286.98435.75120.29Price / CashN/A41.1936.8257.86Price / Book-103.147.487.985.56Net Income-$239.56M-$55.04M$3.16B$248.40M7 Day Performance1.12%2.44%2.40%4.67%1 Month Performance-14.56%1.90%2.19%6.64%1 Year Performance116.49%4.35%33.82%21.31% uniQure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QUREuniQure2.1077 of 5 stars$14.44+0.9%$37.82+161.9%+282.0%$783.84M$27.12M-3.29500PTGXProtagonist Therapeutics2.3249 of 5 stars$49.87-2.3%$66.10+32.5%+43.3%$3.09B$434.43M66.49120VKTXViking Therapeutics3.8522 of 5 stars$27.51-2.4%$87.15+216.8%-40.8%$3.09BN/A-23.9220MLTXMoonLake Immunotherapeutics1.982 of 5 stars$47.50-2.8%$74.50+56.8%+7.4%$3.04BN/A-20.652Positive NewsMTSRMetseraN/A$28.39-3.6%$55.00+93.7%N/A$2.98BN/A0.0081MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730KYMRKymera Therapeutics3.1604 of 5 stars$43.81-2.2%$59.11+34.9%+35.9%$2.85B$47.07M-14.13170IMVTImmunovant1.3868 of 5 stars$16.42-3.1%$38.33+133.5%-38.9%$2.81BN/A-5.99120News CoverageCRNXCrinetics Pharmaceuticals3.1457 of 5 stars$29.06-2.5%$71.75+146.9%-35.3%$2.72B$1.04M-7.61210ALVOAlvotech3.5802 of 5 stars$9.02-1.8%$18.00+99.6%-27.5%$2.72B$491.98M24.381,032HCMHUTCHMED1.3224 of 5 stars$15.42-2.5%$19.00+23.2%-4.6%$2.69B$630.20M0.001,811Gap Up Related Companies and Tools Related Companies PTGX Alternatives VKTX Alternatives MLTX Alternatives MTSR Alternatives MOR Alternatives KYMR Alternatives IMVT Alternatives CRNX Alternatives ALVO Alternatives HCM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:QURE) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding uniQure N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share uniQure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free QURE Stock Alerts